Follow
Michelle Ho
Michelle Ho
Postdoctoral Fellow, National Cancer Institute
Verified email at ucla.edu
Title
Cited by
Cited by
Year
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
MD Hoban, GJ Cost, MC Mendel, Z Romero, ML Kaufman, AV Joglekar, ...
Blood, The Journal of the American Society of Hematology 125 (17), 2597-2604, 2015
3672015
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
MD Hoban, GJ Cost, MC Mendel, Z Romero, ML Kaufman, AV Joglekar, ...
Blood, The Journal of the American Society of Hematology 125 (17), 2597-2604, 2015
3672015
CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells
MD Hoban, D Lumaquin, CY Kuo, Z Romero, J Long, M Ho, CS Young, ...
Molecular Therapy 24 (9), 1561-1569, 2016
2252016
High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency
M Takahashi, X Wu, M Ho, P Chomchan, JJ Rossi, JC Burnett, J Zhou
Scientific reports 6 (1), 1-14, 2016
1022016
AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments
P Dao, J Hoinka, M Takahashi, J Zhou, M Ho, Y Wang, F Costa, JJ Rossi, ...
Cell Systems 3 (1), 62-70, 2016
702016
Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries
AR Banday, ML Stanifer, O Florez-Vargas, OO Onabajo, BW Papenberg, ...
Nature Genetics, 1-14, 2022
632022
HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice
EH Gschweng, MN McCracken, ML Kaufman, M Ho, RP Hollis, X Wang, ...
Cancer research 74 (18), 5173-5183, 2014
382014
Dissecting the Mechanism of Histone Deacetylase Inhibitors to Enhance the Activity of Zinc Finger Nucleases Delivered by Integrase-Defective Lentiviral Vectors
AV Joglekar, L Stein, M Ho, MD Hoban, RP Hollis, DB Kohn
Human gene therapy 25 (7), 599-608, 2014
222014
Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies
SM Larson, A Tu, S Senadheera, M Ho, DB Kohn, S deOliveira
Blood, The Journal of the American Society of Hematology 122 (21), 1659-1659, 2013
172013
338. Evaluation of TALENs and the CRISPR/Cas9 Nuclease System To Correct the Sickle Cell Disease Mutation
MD Hoban, D Lumaquin, C Kuo, Z Romero, C Young, M Ho, J Long, ...
Molecular Therapy 23, S135, 2015
32015
Development of a CRISPR/Cas9 System for Mitochondrial Diseases
M Ho, AH Pham, JJ Rossi, JC Burnett
MOLECULAR THERAPY 28 (4), 39-40, 2020
2020
Site-Specific Correction of the Sickle Mutation in CD34+ Cells Using Zinc Finger Nucleases
MD Hoban, AV Joglekar, D Gray, ML Kaufman, M Ho, Z Romero, ...
MOLECULAR THERAPY 22, S291-S291, 2014
2014
Optimization and Characterization of Product Manufacturing for a Clinical Trial of Gene Therapy for Sickle Cell Disease
F Urbinati, B Campo, J Wherley, S Geiger, ML Kaufman, AR Cooper, ...
MOLECULAR THERAPY 22, S16-S16, 2014
2014
A Pre-Clinical Model Of Hematopoietic Stem Cell Based Immunotherapy For Cancer Utilizing The NY-ESO-1 T-Cell Receptor and sr39TK PET Reporter/Suicide Gene
EH Gschweng, MN McCracken, T Chodon, RC Koya, ML Kaufman, M Ho, ...
Blood, The Journal of the American Society of Hematology 122 (21), 2020-2020, 2013
2013
Enhancing the Efficiency of Zinc Finger Nuclease Delivery by Integrase-Defective Lentiviral Vectors Using Valproic Acid
AV Joglekar, M Ho, L Stein, S Sanadiki, RP Hollis, DB Kohn
MOLECULAR THERAPY 21, S190-S190, 2013
2013
The system can't perform the operation now. Try again later.
Articles 1–15